Буковинський Державний Медичний Університет Моз України
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Буковинський Державний Медичний Університет Моз УкраїниfiledCriticalБуковинський Державний Медичний Університет Моз України
Priority to UAU201405461UpriorityCriticalpatent/UA93429U/en
Publication of UA93429UpublicationCriticalpatent/UA93429U/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The method for improving the efficacy of preventing cardiovascular complications in the patients with osteoarthrosis provides for aspirin 100 mg once a day. In addition, at high risk of vascular events L-arginine (Tivortin) is used at a dose of 5 mL thrice a day for 4-6 weeks followed by quercetin 40 mg twice daily for 4-6 months. In case of moderate degree of vascular risk, L-arginine (Tivortin) is used at a dose of 5 mL thrice a day for 3 weeks followed by quercetin 40 mg twice daily for 3 months.
UAU201405461U2014-05-222014-05-22Method for improving efficacy of preventing cardiovascular complications in patients with osteoarthrosis
UA93429U
(en)